Antiprotozoal activity profiling of approved drugs: A starting point toward drug repositioning

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Kaiser, Marcel ^a,b   Mäser, Pascal ^a,b   Tadoori, Leela Pavan ^c   Ioset, Jean Robert ^c   Brun, Reto ^a,b   Sullivan, David J ^d  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Drugs for Neglected Diseases Initiative   (Switzerland)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMPHOTERICIN B; ARTESUNATE; AURANOFIN; CHLOROQUINE; CICLOPIROXOLAMINE; CLOFAZIMINE; CLOMIPRAMINE; LONIDAMINE; MEFLOQUINE; NIFUROXAZIDE; NIFURTIMOX; NITROFURANTOIN; NORTRIPTYLINE; PAROXETINE; PENTAMIDINE; PIZOTIFEN; PROMAZINE; RIFAMPICIN; RIFAMYCIN; RIFAXIMIN; SERTRALINE; SITAMAQUINE; TAFENOQUINE; THIORIDAZINE; TIPRANAVIR; TOLNAFTATE; TRIFLUPROMAZINE; TROGLITAZONE; UNINDEXED DRUG; ANTIPROTOZOAL AGENT;

AFRICAN TRYPANOSOMIASIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; FEMALE; IC50; IN VITRO STUDY; LEISHMANIA DONOVANI; LEISHMANIASIS; MALARIA; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMA CRUZI; ANIMAL; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; DRUG REPOSITIONING; HUMAN; NEGLECTED DISEASES; PARASITOLOGY; PERITONEUM MACROPHAGE; PRECLINICAL STUDY; PROCEDURES; TRYPANOSOMIASIS, AFRICAN;

ANIMALS; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; CHAGAS DISEASE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG REPOSITIONING; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS; MACROPHAGES, PERITONEAL; MALARIA; MICE; NEGLECTED DISEASES; PLASMODIUM FALCIPARUM; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS, AFRICAN;

EID: 84942927242     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135556     Document Type: Article

References (67)

1. Hotez P, Ottesen E, Fenwick A, Molyneux D (2006) The neglected tropical diseases: The ancient afflictions of stigma and poverty and the prospects for their control and elimination. Adv Exp Med Biol 582:23-33 PMID: 16802616
2. World Health Organization (2014) Media centre. Leishmaniasis Fact sheet No 375, Updated January 2014. Available: www.who.int/mediacentre/factsheets/fs375.
3. World Health Organization (2014) Media centre. Trypanosomiasis, human African (sleeping sickness) Fact sheet No 259, Updated March 2014. Available: www.who.int/mediacentre/factsheets/fs259.
4. World Health Organization (2013) Media centre. Chagas disease (American trypanosoniasis) Fact sheet No 340, Updated March 2013. Available: www.who.int/mediacentre/factsheets/fs340.
5. World Health Organization (2014) Media centre. Malaria Fact sheet No 94, Updated December 2014. Available: www.who.int/mediacentre/factsheets/fs094.
6. Noedl H, Se Y, Schaecher K., Smith BL, Socheat D, Fukuda M.M. (2008) Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. Evidence of artemisinin-resistant malaria in western Cambodia. N EnglJ Med 359: 2619-2620. doi: 10.1056/nejmc0805011 PMID: 19064625
7. Hughes JP, Rees S, Kalindjian S.B., Philpott K.L. (2011) Principles of early drug discovery. Br J Pharmacol 162(6):1239-1249. doi: 10.1111/j.1476-5381.2010.01127.x PMID: 21091654
8. Royle KE, Jimenez del Val I, Kontoravdi C (2013) Integration of models and experimentation to optimise the production of potential biotherapeutics. Drug Discov Today 18(23-24):1250-1255. doi: 10.1016/j. drudis.2013.07.002 PMID: 23850703
9. DNDi (2013) Target Product Profiles. Available: http://www.dndi.org/diseases-projects/diseases.html.
10. MMV (2013) Target Product Profiles. Available: http://www.mmv.org/research-development/essential-information-scientists.
11. Weisman JL, Liou AP, Shelat A.A., Cohen FE, Guy RK, De Risi JL (2006) Searching for new antimalarial therapeutics amongst known drugs. Chem Biol Drug Des. 2006 67(6):409-16. PMID: 16882315
12. Chong CR, Sullivan DJ Jr (2007) New uses for old drugs. Nature 9; 448 (7154):645-6.
13. Orhan I, Şener B, Kaiser M, Brun R, Tasdemir D (2010) Inhibitory activity of marine sponge-derived natural products against parasitic protozoa. Mar. Drugs 8: 47-58. doi: 10.3390/md8010047 PMID: 20161970
14. Don R, Ioset J.R. (2014) Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. Parasitology 141(1):140-146. doi: 10.1017/S003118201300142X PMID: 23985066
15. MMV (2008) Compound progression criteria. Available: http://www.mmv.org/research-development/essential-information-scientists.
16. Sun T, Zhang Y. (2008) Pentamidine binds to tRNA through non-specific hydrophobic interactions and inhibits aminoacylation and translation. Nucleic Acids Res 36(5):1654-1664. doi: 10.1093/nar/gkm1180 PMID: 18263620
17. Mathis AM Holman JL, Sturk LM, Ismail MA, Boykin DW, Tidwell RR, et al. (2006) Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African try-panosomes. Antimicrob Agents Chemother 50:2185-2191. PMID: 16723581
18. Boiani M, Piacenza L, Hernández P, Boiani L., Cerecetto H, González M, et al. (2010) Mode of action of Nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: Is oxidative stress involved? Biochem Pharmacol 79(12):1736-1745. doi: 10.1016/j.bcp.2010.02.009 PMID: 20178775
19. Hall BS, Bot C, Wilkinson SR (2011) Nifurtimox Activation by Trypanosomal Type I Nitroreductases Generates Cytotoxic Nitrile Metabolites. J Biol Chem 286(15):13088-13095. doi: 10.1074/jbc.M111. 230847 PMID: 21345801
20. Torreele E, Bourdin Trunz B, Tweats D, Kaiser M., Brun R, Mazué G, et al. (2010) Fexinidazole - A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness. PLoS NeglTrop Dis 4(12):e923. doi: 10.1371/journal.pntd.0000923 PMID: 21200426
21. Tweats D, Trunz BB, Torreele E (2012) Genotoxicity profile of fexinidazole-a drug candidate in clinical development for human African trypanomiasis (sleeping sickness). Mutagenesis 27(5):523-532. doi: 10.1093/mutage/ges015 PMID: 22539226
22. Jeon KI, Byun MS, Jue D.M. (2003) Gold compound auranofin inhibits I kappa B kinase (IKK) by modifying Cys-179 of IKK beta subunit. Exp Mol Med 35(2):61-66. PMID: 12754408
23. Lobanov AV, Gromer S, Salinas G, Gladyshev V.N. (2006) Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastida-specific selenoprotein. Nucleic Acids Res 34(14):4012-4024. PMID: 16914442
24. Debnath A, Parsonage D, Andrade R.M., He C, Cobo ER, Hirate K, et al. (2012) A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med 18(6):956-960. doi: 10.1038/nm.2758 PMID: 22610278
25. Intoccia AP, Flanagan TL, Walz DT, Gutzait L, Swagzdis JE, Flagiello J Jr, et al. (1982) Pharmacokinetics of auranofin in animals. J Rheumatol Suppl 8:90-98. PMID: 6813497
26. Kelly JM, Miles MA, Skinner A.C. (1999) The anti-influenza virus drug rimantadine has trypanocidal activity. Antimicrob Agents Chemother 43(4):985-987. PMID: 10103219
27. Kelly JM, Quack G, Miles M.M. (2001) In vitro and in vivo activities of aminoadamantane and aminoalkyl-cyclohexane derivatives against Trypanosoma brucei. Antimicrob Agents Chemother 45(5):1360-1366. PMID: 11302796
28. Zoidis G, Tsotinis A, Kolocouris N., Kelly JM, Prathalingam SR, Naesens L, et al (2008) Design and synthesis of bioactive 1,2-annulated adamantane derivatives. Org Biomol Chem 6(17):3177-3185. doi: 10.1039/b804907f PMID: 18698478
29. Pinto LH, Lamb R.A. (1995) Understanding the mechanism of action of the anti-influenza virus drug amantadine. Trends Microbiol 3(7):271. PMID: 7551640
30. Griffin SD, Beales LP, Clarke D.S., Worsfold O, Evans SD, Jaeger J, et al. (2003) The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Letters 535 (1-3):34-38. PMID: 12560074
31. Hayden FG, Gwaltney JM Jr, Van de Castle RL, Adams KF, Giordani B (1981) Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother 19(2):226-233. PMID: 7347558
32. Wills RJ, Farolino DA, Choma N, Keigher N. (1987) Rimantadine pharmacokinetics after single and multiple doses. Antimicrob Agents Chemother 31(5):826-828. PMID: 3606083
33. Hayden FG, Minocha A, Spyker D.A., Hoffman H.E. (1985) Comparative single-dose pharmacokinetics of amantadine and rimantadine hydrochloride in young and elderly adults. Antimicrob Agents Chemother 28(2):216-221. PMID: 3834831
34. Spector R (1988) Transport of amantadine and rimantadine through the blood-brain barrier. J Pharmacol ExpTher 244(2):516-519. PMID: 3346834
35. Chibale K, Visser M, Yardley V., Croft SL, Fairlamb AH (2000) Synthesis and evaluation of 9,9-dimethyl-xanthene tricyclics against trypanothione reductase, Trypanosoma brucei, Trypanosoma cruzi and Leishmania donovani. Bioorg Med Chem Lett 10(11):1147-1150. PMID: 10866368
36. Richardson JL, Nett IRE, Jones DC, Abdille M.H., Gilbert IH, Fairlamb AH (2009) Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis. ChemMedChem 4(8):1333-1340. doi: 10.1002/cmdc.200900097 PMID: 19557801
37. Wilkinson SR, Taylor MC, Horn D, Kelly J.M., Cheeseman I. (2008) A mechanism for cross-resistance to nifurtimoxand benznidazole intrypanosomes. Proc Natl Acad Sci U S A 105(13):5022-5027. doi: 10.1073/pnas.0711014105 PMID: 18367671
38. Bahia MT, deAndrade IM, Martins TA, do NascimentoÁ F, Diniz Lde F, Caldas IS, et al. (2012) Fexinidazole: A Potential New Drug Candidate for Chagas Disease. PLoS NeglTrop Dis 6(11):e1870. doi: 10.1371/journal.pntd.0001870 PMID: 23133682
39. Ghannoum MA, Rice LB (1999) Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12(4):501-517. PMID: 10515900
40. Molina I, Gómez i Prat J, Salvador F, Treviño B, Sulleiro E, Serre N, et al. (2014) Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 370(20):1899-1908. doi: 10.1056/NEJMoa1313122 PMID: 24827034
41. Moraes CB, Giardini MA, Kim H, Franco C.H., Araujo-Junior AM, Schenkman S, et al (2014) Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Sci Rep 4: 4703. doi: 10.1038/srep04703 PMID: 24736467
42. Seebeck T, Sterk GJ, Ke H (2011) Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite. Future MedChem 3(10):1289-1306. doi: 10.4155/fmc.11.77 PMID: 21859303
43. Wang H, Kunz S, Chen G., Seebeck T, Wan Y, Robinson H, et al. (2012) Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors. J BiolChem. 2012 Apr 6; 287(15):11788-97. doi: 10.1074/jbc.M111.326777 PMID: 22356915
44. Jansen C, Wang H, Kooistra AJ, de Graaf C, Orrling KM, Tenor H, et al. (2013) Discovery of novel Trypanosoma brucei phosphodiesterase B1 inhibitors by virtual screening against the unliganded TbrPDEB1 crystal structure. J Med Chem. 2013 Mar 14; 56(5):2087-96. doi: 10.1021/jm3017877 PMID: 23409953
45. Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, et al. (2011) Identification of Novel Functional Inhibitors of Acid Sphingomyelinase. PLoSOne 6(8):e23852. doi: 10.1371/journal. pone.0023852 PMID: 21909365
46. De Rycker M, Hallyburton I, Thomas J., Campbell L, Wyllie S, Joshi D, et al. (2013) Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay. Antimicrob Agents Chemother 57(7):2913-2922. doi: 10.1128/AAC.02398-12 PMID: 23571538
47. Baginski M, Czub J. (2009) Amphotericin B and Its New Derivatives - Mode of Action. Curr Drug Metab 10(5):459-469. PMID: 19689243
48. Loiseau PM, Cojean S, Schrevel J. (2011) Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance. Parasite 18(2):115-119. PMID: 21678786
49. Cholo MC, Steel HC, Fourie P.B., Germishuizen WA, Anderson R. (2012) Clofazimine: current status and future prospects. J Antimicrob Chemother 67(2):290-298. doi: 10.1093/jac/dkr444 PMID: 22020137
50. Baik J, Rosania GR (2012) Macrophages Sequester Clofazimine in an Intracellular Liquid Crystal-Like SupramolecularOrganization. PLoSOne 7(10):e47494. doi: 10.1371/journal.pone.0047494 PMID: 23071814
51. Evans AT, Croft SL, Peters W, Neal R.A. (1989) Antileishmanial effects of clofazimine and other antimy-cobacterial agents. Ann Trop Med Parasitol 83(5):447-454. PMID: 2619361
52. Arbiser JL, Moschella SL (1995) Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol 32(2 Pt 1):241-247. PMID: 7829710
53. Davis DA, Soule EE, Davidoff K.S., Daniels SI, Naiman NE, Yarchoan R (2012) Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing. Antimicrob Agents Chemother 56(7):3620-3628. doi: 10.1128/AAC.00055-12 PMID: 22508308
54. Sharlow ER, Leimgruber S, Murray S, Lira A., Sciotti RJ, Hickman M, et al. (2014) Auranofin is an apo-ptosis-simulating agent with in vitro and in vivo anti-leishmanial activity. ACS Chem Biol. 2014 Mar 21; 9(3):663-72. doi: 10.1021/cb400800q PMID: 24328400
55. Penna-Coutinho J., Cortopassi WA, Oliveira AA, Franca TCC, Krettli AU (2011) Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies. PLoSOne 6(7):e21237. doi: 10.1371/journal.pone.0021237 PMID: 21779323
56. Alger NE, Spira DT, Silverman P.H. (1970) Inhibition of rodent malaria in mice by rifampicin. Nature 227 (5256):381-382.
57. Strath M, Scottfinnigan T, Gardner M., Williamson D, Wilson I. (1993) Antimalarial activity of rifampicin in vitro and in rodent models. Trans R Soc Trop Med Hyg 87(2):211-216. PMID: 8337732
58. Bitonti AJ, Sjoerdsma A, McCann PP, Kyle DE, Oduola AM, Rossan RN, et al. (1988) Reversal of chlo-roquine resistance in malaria parasite Plasmodium falciparum by desipramine. Science 242 (4883):1301-1303. PMID: 3057629
59. Eastman RT, Pattaradilokrat S, Raj D.K., Dixit S., Deng B, Miura K, et al. (2013) A class of tricyclic compounds blocking malaria parasite oocyst development and transmission. Antimicrob Agents Chemother 57(1):425-435. doi: 10.1128/AAC.00920-12 PMID: 23129054
60. Akaki M, Nakano Y, Ito Y., Nagayasu E, Aikawa M. (2002) Effects of dipyridamole on Plasmodium falcip-arum-infected erythrocytes. Parasitol Res 88(12):1044-1050. PMID: 12444453
61. Mahmoudi N, Garcia-Domenech R, Galvez J., Farhati K, Franetich JF, Sauerwein R, et al (2008) New active drugs against liver stages of Plasmodium predicted by molecular topology. Antimicrob Agents Chemother 52(4):1215-1220. doi: 10.1128/AAC.01043-07 PMID: 18212104
62. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3(8):673-683. PMID: 15286734
63. Jin G, Wong S.T. (2014) Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 19(5):637-644. doi: 10.1016/j.drudis.2013 PMID: 24239728
64. Nzila A, Ma Z, Chibale K. (2011) Drug repositioning in the treatment of malaria and TB. Future Med Chem 3(11): 1413-1426. doi: 10.4155/fmc.11.95 PMID: 21879845
65. Padhy BM, Gupta Y.K. (2011) Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med 57(2):153-160. doi: 10.4103/0022-3859.81870 PMID: 21654146
66. Swinney DC, Anthony J. (2011) How were new medicines discovered? Nat Rev Drug Discov 10 (7):507-519. doi: 10.1038/nrd3480 PMID: 21701501
67. Chong CR, Chen X, Shi L., Liu JO, Sullivan DJ Jr (2006) A clinical drug library screen identifies astemi-zole as an antimalarial agent. Nat Chem Biol 2(8):415-416. PMID: 16816845